Hims & Hers jumps 6% as five states expand an FTC-linked challenge, while Eli Lilly slides and Novo Nordisk stays flat

Hims & Hers shares climbed about 6% following a sharp prior drop, even as legal scrutiny around the company’s business model intensified. A separate development highlighted in the market coverage was that five states had joined an FTC-linked lawsuit, a move that has kept pressure on the consumer health platform front of mind for investors.

The optimism in Hims & Hers stock came despite the expanding antitrust backdrop. The day’s trading suggested that investors were weighing a near-term bounce against longer-term uncertainty tied to regulators’ claims, rather than treating the lawsuit headline as an immediate deal-breaker.

Within the same report, two large drugmakers connected to the supply chain of popular prescriptions were described as not participating in the broader share strength. Eli Lilly was said to have dipped, while Novo Nordisk was portrayed as holding steady, implying the market was differentiating among healthcare names even when the catalyst was not company-specific.

That split also points to how investors often parse exposure in industries where costs, pricing, and distribution are affected by regulation indirectly. Antitrust suits can shape expectations for marketing practices, channel partnerships, and contracting terms, but those effects may hit different participants at different times.

For Hims & Hers, the key swing factor is not just the existence of litigation, but what the expanded complaint could mean for its operating strategy. The report’s framing around an FTC-linked case joining multiple states suggests regulators are seeking broader remedies than would be available through the FTC alone, potentially increasing the odds of structural or behavioral constraints.